Original Article | Published:

Integrative Biology

Decreased lipid metabolism but increased FA biosynthesis are coupled with changes in liver microRNAs in obese subjects with NAFLD

International Journal of Obesity volume 41, pages 620630 (2017) | Download Citation

Abstract

Background/Objective:

Many controversies regarding the association of liver miRNAs with obesity and nonalcoholic fatty liver diseases (NAFLD) call for additional validations. This study sought to investigate variations in genes and hepatic miRNAs in a sample of obese patients with or without NAFLD and human hepatocytes (HH).

Subjects/Methods:

A total of 60 non-consecutive obese women following bariatric surgery were recruited. Subjects were classified as NAFLD (n=17), borderline (n=24) and controls (n=19) with normal enzymatic profile, liver histology and ultrasound assessments. Profiling of 744 miRNAs was performed in 8 obese women with no sign of hepatic disease and 11 NAFLD patients. Additional validation and expression of genes related to de novo fatty acid (FA) biosynthesis, uptake, transport and β-oxidation; glucose metabolism, and inflammation was tested in the extended sample. Induction of NAFLD-related genes and miRNAs was examined in HepG2 cells and primary HH treated with palmitic acid (PA), a combination of palmitate and oleic acid, or high glucose, and insulin (HG) mimicking insulin resistance in NAFLD.

Results:

In the discovery sample, 14 miRNAs were associated with NAFLD. Analyses in the extended sample confirmed decreased miR-139-5p, miR-30b-5p, miR-122-5p and miR-422a, and increased miR-146b-5p in obese subjects with NAFLD. Multiple linear regression analyses disclosed that NAFLD contributed independently to explain miR-139-5p (P=0.005), miR-30b-5p (P=0.005), miR-122-5p (P=0.021), miR-422a (P=0.007) and miR-146a (P=0.033) expression variance after controlling for confounders. Decreased miR-122-5p in liver was associated with impaired FA usage. Expression of inflammatory and macrophage-related genes was opposite to decreased miR-30b-5p, miR-139-5p and miR-422a, whereas increased miR-146b-5p was associated with FABP4 and decreased glucose metabolism and FA mobilization. In partial agreement, PA (but not HG) led to decreased miR-139-5p, miR-30b-5p, miR-422a and miR-146a in vitro, in parallel with increased lipogenesis and FA transport, decreased glucose metabolism and diminished FA oxidation.

Conclusion:

This study confirms decreased liver glucose and lipid metabolism but increased FA biosynthesis coupled with changes in five unique miRNAs in obese patients with NAFLD.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , . A concise review of non-alcoholic fatty liver disease. Atherosclerosis 2015; 239: 192–202.

  2. 2.

    , . Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Metabolism 2015; 65: 1080–1086.

  3. 3.

    . Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol 2014; 2: 901–910.

  4. 4.

    . Nutritional modulation of non-alcoholic fatty liver disease and insulin resistance. Nutrients 2015; 7: 9127–9138.

  5. 5.

    , , , , , et al. Altered fatty acid metabolism-related gene expression in liver from morbidly obese women with non-alcoholic fatty liver disease. Int J Mol Sci 2014; 15: 22173–22187.

  6. 6.

    . MicroRNAs in nonalcoholic fatty liver disease. J Clin Med 2015; 4: 1977–1988.

  7. 7.

    . The functions of animal microRNAs. Nature 2004; 431: 350–355.

  8. 8.

    , , , . The microRNA: overview of the RNA gene that modulates gene functions. Methods Mol Biol 2006; 342: 1–18.

  9. 9.

    , , , , . MicroRNAs expressed during viral infection: biomarker potential and therapeutic considerations. Biomark Insights 2016; 10: 25–52.

  10. 10.

    , , , , , et al. HepatomiRNoma: the proposal of a new network of targets for diagnosis, prognosis and therapy in hepatocellular carcinoma. Crit Rev Oncol Hematol 2016; 97: 312–321.

  11. 11.

    , , . Steatosis and steatohepatitis: complex disorders. Int J Mol Sci 2014; 15: 9924–9944.

  12. 12.

    , , , , , et al. Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology 2008; 48: 1810–1820.

  13. 13.

    , , , , , et al. High-throughput sequencing reveals altered expression of hepatic microRNAs in nonalcoholic fatty liver disease-related fibrosis. Transl Res 2015; 166: 304–314.

  14. 14.

    , , , , , et al. Novel hepatic microRNAs upregulated in human nonalcoholic fatty liver disease. Physiol Rep 2016; 4: 1.

  15. 15.

    , , , , , et al. Differential expression of microRNAs in mouse liver under aberrant energy metabolic status. J Lipid Res 2009; 50: 1756–1765.

  16. 16.

    , , , , , et al. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut 2015; 64: 800–812.

  17. 17.

    , , , , , . Aberrant hepatic microRNA expression in nonalcoholic fatty liver disease. Cell Physiol Biochem 2014; 34: 1983–1997.

  18. 18.

    , , , , , et al. Maternal high fat diet during pregnancy and lactation alters hepatic expression of insulin like growth factor-2 and key microRNAs in the adult offspring. BMC Genomics 2009; 10: 478.

  19. 19.

    , , , , , et al. Berberine attenuates development of the hepatic gluconeogenesis and lipid metabolism disorder in type 2 diabetic mice and in palmitate-incubated HepG2 cells through suppression of the HNF-4alpha miR122 pathway. PLoS ONE 2016; 11: e0152097.

  20. 20.

    , , , , , . MiR-146b attenuates high-fat diet-induced non-alcoholic steatohepatitis in mice. J Gastroenterol Hepatol 2015; 30: 933–943.

  21. 21.

    , , , , , et al. Profiling of circulating microRNAs reveals common microRNAs linked to type 2 diabetes that change with insulin sensitization. Diabetes Care 2014; 37: 1375–1383.

  22. 22.

    , , . Palmitate-induced apoptosis can occur through a ceramide-independent pathway. J Biol Chem 2001; 276: 14890–14895.

  23. 23.

    , , , , , . Differential lipotoxic effects of palmitate and oleate in activated human hepatic stellate cells and epithelial hepatoma cells. Cell Physiol Biochem 2016; 39: 1648–1662.

  24. 24.

    , , , , , et al. 4-Hydroxyisoleucine improves insulin resistance in HepG2 cells by decreasing TNF-alpha and regulating the expression of insulin signal transduction proteins. Mol Med Rep 2015; 12: 6555–6560.

  25. 25.

    , . SH2 domain-containing inositol 5-phosphatase (SHIP2) inhibition ameliorates high glucose-induced de-novo lipogenesis and VLDL production through regulating AMPK/mTOR/SREBP1 pathway and ROS production in HepG2 cells. Free Radic Biol Med 2015; 89: 679–689.

  26. 26.

    , , , , , . Saponins from Platycodon grandiflorum inhibit hepatic lipogenesis through induction of SIRT1 and activation of AMP-activated protein kinase in high-glucose-induced HepG2 cells. Food Chem 2013; 140: 115–123.

  27. 27.

    , , , , , et al. Inflammation triggers specific microRNA profiles in human adipocytes and macrophages and in their supernatants. Clin Epigenetics 2015; 7: 49.

  28. 28.

    , . The use of relative operating characteristic (ROC) curves in test performance evaluation. Arch Pathol Lab Med 1986; 110: 13–20.

  29. 29.

    , , , , , et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3: RESEARCH0034.

  30. 30.

    , , , , , et al. Gene expression patterns in hepatic tissue and visceral adipose tissue of patients with non-alcoholic fatty liver disease. Obes Surg 2007; 17: 1111–1118.

  31. 31.

    , , , , , et al. A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology 2005; 42: 665–674.

  32. 32.

    , , , , , et al. The Scap/SREBP pathway is essential for developing diabetic fatty liver and carbohydrate-induced hypertriglyceridemia in animals. Cell Metab 2012; 15: 240–246.

  33. 33.

    , , , , , et al. Protection from non-alcoholic steatohepatitis and liver tumourigenesis in high fat-fed insulin receptor substrate-1-knockout mice despite insulin resistance. Diabetologia 2012; 55: 3382–3391.

  34. 34.

    . MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215–233.

  35. 35.

    , , , , , et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005; 433: 769–773.

  36. 36.

    , , , , , . Determinants of targeting by endogenous and exogenous microRNAs and siRNAs. RNA 2007; 13: 1894–1910.

  37. 37.

    , . MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets. J Clin Invest 2007; 117: 2369–2376.

  38. 38.

    , , , , , et al. Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease. Int J Mol Med 2007; 20: 351–358.

  39. 39.

    , , . Genomic aspects of NAFLD pathogenesis. Genomics 2013; 102: 84–95.

  40. 40.

    , , , , . MicroRNA-370 controls the expression of microRNA-122 and Cpt1alpha and affects lipid metabolism. J Lipid Res 2010; 51: 1513–1523.

  41. 41.

    , , , , , et al. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab 2011; 13: 376–388.

  42. 42.

    . AMPK: a key regulator of energy balance in the single cell and the whole organism. Int J Obes (Lond) 2008; 32: S7–S12.

  43. 43.

    , , . S6 kinase 2 deficiency enhances ketone body production and increases peroxisome proliferator-activated receptor alpha activity in the liver. Hepatology 2012; 55: 1727–1737.

  44. 44.

    , . The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat Cell Biol 2011; 13: 1016–1023.

  45. 45.

    , . MicroRNAs in liver disease. Nat Rev Gastroenterol Hepatol 2013; 10: 542–552.

  46. 46.

    , , , , , et al. Role of microRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid-defined diet in C57BL/6 mice. Hepatology 2009; 50: 1152–1161.

  47. 47.

    , , , . A putative role of micro RNA in regulation of cholesterol 7alpha-hydroxylase expression in human hepatocytes. J Lipid Res 2010; 51: 2223–2233.

  48. 48.

    , , , , , et al. Double-negative feedback loop between microRNA-422a and forkhead box (FOX)G1/Q1/E1 regulates hepatocellular carcinoma tumor growth and metastasis. Hepatology 2015; 61: 561–573.

  49. 49.

    , , , , , et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005; 438: 685–689.

  50. 50.

    , , , , , et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 2006; 3: 87–98.

  51. 51.

    , , , , , et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest 2012; 122: 2884–2897.

  52. 52.

    , , , , , et al. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest 2012; 122: 2871–2883.

  53. 53.

    , , , , , et al. Identification of postoperative prognostic microRNA predictors in hepatocellular carcinoma. PLoS ONE 2012; 7: e37188.

  54. 54.

    , , , , . MicroRNA expression profiling in HCV-infected human hepatoma cells identifies potential anti-viral targets induced by interferon-alpha. PLoS ONE 2013; 8: e55733.

  55. 55.

    , , . MicroRNAs in adipose tissue: their role in adipogenesis and obesity. Int J Obes (Lond) 2013; 37: 325–332.

  56. 56.

    , , , , , et al. Weight-reduction through a low-fat diet causes differential expression of circulating microRNAs in obese C57BL/6 mice. BMC Genomics 2015; 16: 699.

  57. 57.

    , , , , , . Identification of a two-layer regulatory network of proliferation-related microRNAs in hepatoma cells. Nucleic Acids Res 2012; 40: 10478–10493.

  58. 58.

    , , , . NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 2006; 103: 12481–12486.

Download references

Acknowledgements

This study was supported by the European Project FLORINASH-FP7-HEALTH-2009-2.4.5-1, the CIBER de la Fisiopatología de la Obesidad y la Nutrición (CIBERobn), by funds from the Agència de Gestió d’Ajuts Universitaris de Recerca (AGAUR, FI-DGR 2015 to Jèssica Latorre), and the Fondo Europeo de Desarrollo Regional (FEDER). The CIBERobn is an initiative from the Instituto de Salud Carlos III (ISCIII). This study is indebted to the IDIBGI Biobank, integrated in the Spanish National Biobank Network, for the sample and data procurement. Dr Josep M Mercader was supported by a Sara Borrell fellowship, also from the Instituto de Salud Carlos III (ISCIII). Dr Francisco J Ortega is the guarantor for this work as a whole, including study design, access to data and the decision to submit and publish the manuscript.

Author information

Affiliations

  1. Department of Diabetes, Endocrinology and Nutrition (UDEN), Institut d’Investigació Biomédica de Girona (IdIBGi), Hospital of Girona ‘Dr Josep Trueta’ Carretera de França s/n, Girona, Spain

    • J Latorre
    • , J M Moreno-Navarrete
    • , M Sabater
    • , Ò Rovira
    • , W Ricart
    • , J M Fernández-Real
    •  & F J Ortega
  2. CIBER de la Fisiopatología de la Obesidad y la Nutrición (CIBERobn) and Instituto de Salud Carlos III (ISCIII), Madrid, Spain

    • J M Moreno-Navarrete
    • , M Sabater
    • , W Ricart
    • , J M Fernández-Real
    •  & F J Ortega
  3. Joint BSC-CRG-IRB Research Program in Computational Biology, Barcelona Supercomputing Center, Barcelona, Spain

    • J M Mercader
  4. Department of Surgery, Hospital Dr. Josep Trueta of Girona, Girona, Spain

    • J Gironès

Authors

  1. Search for J Latorre in:

  2. Search for J M Moreno-Navarrete in:

  3. Search for J M Mercader in:

  4. Search for M Sabater in:

  5. Search for Ò Rovira in:

  6. Search for J Gironès in:

  7. Search for W Ricart in:

  8. Search for J M Fernández-Real in:

  9. Search for F J Ortega in:

Competing interests

The authors declare no conflict of interest.

Corresponding author

Correspondence to F J Ortega.

Supplementary information

About this article

Publication history

Received

Revised

Accepted

Published

DOI

https://doi.org/10.1038/ijo.2017.21

Supplementary Information accompanies this paper on International Journal of Obesity website (http://www.nature.com/ijo)